REACTION, NCT03610711: (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer |
|
|
| Active, not recruiting | 1/2 | 21 | US | Nivolumab, Optivo, Relatlimab, anti-LAG3 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb | Gastroesophageal Cancer, Immune Checkpoint Inhibition | 12/24 | 04/25 | | |
CHI-RON, NCT05185232: Congenital Heart Initiative-Redefining Outcomes and Navigation to Adult Centered Care |
|
|
| Not yet recruiting | N/A | 3000 | US | Impact of gaps in care/loss to healthcare follow-up | Children's National Research Institute, Patient-Centered Outcomes Research Institute, Louisiana Public Health Institute | Congenital Heart Disease, Comorbidities and Coexisting Conditions | 10/23 | 06/24 | | |
